Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings

TA-125 tracks the 125 largest and most prominent companies on the TASE

JERUSALEM, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq and TASE: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that its ordinary shares will be included in the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective Nov. 5, 2026.

Alpha Tau’s ordinary shares have been dual listed on the Nasdaq and TASE markets since August 2026, and trade on the TASE under the Hebrew symbol דרטס, allowing investors the flexibility to trade in both US and Israeli currency during open trading hours of the respective markets.

The TA-125 index, considered by many Israeli investors to be the benchmark for assessing the TASE market, tracks 125 of the largest and most prominent companies traded on the TASE: the 35 companies in the exchange’s leading TA-35 index and the 90 companies in the TA-90 index. These indices are widely followed by Israeli investors, and the index funds that track them are expected to add Alpha Tau’s shares to their holdings. With its inclusion, Alpha Tau will be one of only three biomed companies in the TA-125.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.